References
- Maxwell JC, Mendelson B. What do we know now about the impact of the laws related to Marijuana? J Addict Med. 2016;10:3–12. doi:https://doi.org/10.1097/ADM.0000000000000188.
- WHO. Management of substance abuse - Cannabis. Geneva: Switzerland; 2020. https://www.who.int/substance_abuse/facts/cannabis/en/:
- Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8:e76635.
- Compton WM, Han B, Jones CM, Blanco C. Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. Drug Alcohol Depend. 2019;204:107468.
- Leyton M. Cannabis legalization: did we make a mistake? Update 2019. J Psychiatry Neurosci. 2019;44:291–93. doi:https://doi.org/10.1503/jpn.190136.
- Canada S. National Cannabis Survey, first quarter 2019. 2019; Available from: https://www150.statcan.gc.ca/n1/en/daily-quotidien/190502/dq190502a-eng.pdf?st=TQEzeqzW [last accessed 29 Jun 2021].
- WHO. The Health and social effects of nonmedical cannabis use. Geneva: Switzerland; 2016.
- Sorkhou M, Bedder RH, George TP. The behavioural sequelae of cannabis use in healthy people. Front Psychiatr. 2021;12:630247.
- Gryczynski J, Schwartz RP, O'Gradt KE, Restivo L, Mitchell SG, Jaffe JH. Understanding patterns of high-cost health care use across different substance user groups. Health Aff (Millwood). 2016;35:12–19.
- Khan SS, Secades-Ville R, Okuda M, Wang S, Pérez-Fuentes G, Kerridge BT, Blanco, C. Gender differences in cannabis use disorders: results from the national epidemiologic survey of alcohol and related conditions. Drug Alcohol Depend. 2013;130:101–108.
- Sherman BJ, Baker NL, McRae-Clark AL. Gender differences in cannabis use disorder treatment: change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016;60:197–202. doi:https://doi.org/10.1016/j.addbeh.2016.04.014.
- Kandel DB, Chen K. Types of marijuana users by longitudinal course. J Stud Alcohol. 2000;61:367–78. doi:https://doi.org/10.15288/jsa.2000.61.367.
- Wagner FA, Anthony JC. Male-female differences in the risk of progression from first use to dependence upon cannabis, cocaine, and alcohol. Drug Alcohol Depend. 2007;86:191–98. doi:https://doi.org/10.1016/j.drugalcdep.2006.06.003.
- StatisticsCanada. National Cannabis Survey, second quarter 2019. 2019; Available from: https://www150.statcan.gc.ca/n1/daily-quotidien/190815/dq190815a-eng.htm [last accessed 29 Jun 2021].
- Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions-III. Am J Psychiatry. 2016;173:588–599.
- Lopez-Quintero C, Pérez de los Cabos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend. 2011;115:120–130.
- Assari S, Mistry R, Howard Caldwell C, Zimmerman MA. Marijuana use and depressive symptoms; gender differences in African American adolescents. Front Psychol. 2018;9:2135.
- Crane NA, Langenecker SA, Mermelstein RJ. Gender differences in the associations among marijuana use, cigarette use, and symptoms of depression during adolescence and young adulthood. Addict Behav. 2015;49:33–39. doi:https://doi.org/10.1016/j.addbeh.2015.05.014.
- Al Azizi SA, Omer AA, Mufaddel AA. cannabis use among people with mental illness: clinical and socio-demographic characteristics. Open J Psychiatry. 2018;8:244–52. doi:https://doi.org/10.4236/ojpsych.2018.83021.
- SAMHSA. 2018 National survey on drug use and health: women; 2018. .https://www.samhsa.gov/data/sites/default/files/reports/rpt23250/5_Women_2020_01_14_508.pdf [last accessed 29 Jun 2021].
- Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43:34–51. doi:https://doi.org/10.1038/npp.2017.140.
- Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse. 2002;28:643–52. doi:https://doi.org/10.1081/ADA-120015873.
- Brabete AC, Greaves L, Hemsing N, Stinson J. Sex- and gender-based analysis in cannabis treatment outcomes: a systematic review. Int J Environ Res Public Health. 2020;17.
- Cerda M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, Wall MM, et al. Association between recreational marijuana legalization in the United States and changes in Marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry 2019;77:165–171.
- Camors C, Chavez S, Romi A. The cannabis industry within the USA: the influence of gender on cannabis policy and sales. Sustain Accounting Manage Policy Journal. 2020;11: 1095–126. doi:https://doi.org/10.1108/SAMPJ-12-2018-0330. ahead-of-print.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
- Viechtbauer W. Conducting Meta-Analyses in R with the metafor package. J Stat Software 2010;36:48.
- Hunter JE, Schmidt FL. Fixed effects vs. random effects meta‐analysis models: implications for cumulative research knowledge. Int J Sel Assess. 2000;8:275–92. doi:https://doi.org/10.1111/1468-2389.00156.
- Van Den Noortgate W, Onghena P. Multilevel meta-analysis: a comparison with traditional meta-analytical procedures. Educ Psychol Meas. 2003;63:765–90. doi:https://doi.org/10.1177/0013164403251027.
- Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods. 2006;11:193.
- Stinson FS, RuanWJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36:1447–1460.
- Wu LT, Brandy KT, Mannelli P, Killeen TK. Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study. J Psychiatr Res. 2014;50:26–35.
- Kerridge BT, Pickering R, Chou P, Saha TD, Hasin DS. DSM-5 cannabis use disorder in the national epidemiologic survey on alcohol and related conditions-III: gender-specific profiles. Addict Behav. 2018;76:52–60.
- Farmer RF, Kosty DB, Seeley JR, Gau JM, Duncan SC, Walker DD, Lewinsohn PM. Association of comorbid psychopathology with the duration of cannabis use disorders. Psychol Addict Behav. 2016;30:82–92.
- Haberstick BC, Young SE, Zeiger JS, Hewitt JK, Hopfer CJ. Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend. 2014;136:158–161.
- Lai HM, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse. 2012;38:567–74. doi:https://doi.org/10.3109/00952990.2012.694523.
- Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, et al. Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Aust N Z J Psychiatry. 2012;46:1182–1192.
- Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the national survey of mental health and wellbeing. Addiction. 2001;96:737–48. doi:https://doi.org/10.1046/j.1360-0443.2001.9657379.x.
- Mueser KT, Yarnold PR, Rosenberg SD, Swett C Jr, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull. 2000;26:179–192.
- Zhu H, Wu LT. Sex differences in cannabis use disorder diagnosis involved hospitalizations in the United States. J Addict Med. 2017;11:357–67. doi:https://doi.org/10.1097/ADM.0000000000000330.
- Karam EG, Yabroudi PF, Melhem NM. Comorbidity of substance abuse and other psychiatric disorders in acute general psychiatric admissions: a study from Lebanon. Compr Psychiatry. 2002;43:463–68. doi:https://doi.org/10.1053/comp.2002.35910.
- Machielsen M, van der Sluis S, de Haan L. Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms. Aust N Z J Psychiatry. 2010;44:721–28. doi:https://doi.org/10.3109/00048671003689710.
- Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert, M. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry. 2012;27:463–469.
- Lange EH, Nesvåg R, Ringen PA, Hartberg CB, Haukvik UK, Andreassen OA, et al. One year follow-up of alcohol and illicit substance use in first-episode psychosis: does gender matter? Compr Psychiatry. 2014;55:274–282.
- Brunette MF, Mueser KT, Babbin S, Meyer-Kalos P, Rosenheck R, Correll CU, Cather C, Robinson DG, Schooler NR, Penn DL, et al. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res. 2018;194:4–12.
- Kavanagh DJ, Waghorn G, Jenner L, Chant DC, Carr V, Evans M, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res. 2004;66:115–124.
- Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med. 1998;28:1411–1419.
- DeRosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res. 2010;120:95–100.
- Nesvag R, Knudsen GP, Bakken IJ, Høye A, Ystrom E, Surén P, et al. Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol. 2015;50:1267–1276.
- Libuy N, de Angel V, Ibáñez C, Murray RM, Mundt AP. The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. Schizophr Res. 2018;194:13–17.
- Dubertret C, Bidard I, Adès J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res. 2006;86:284–290.
- Harder VS, Stuart EA, Anthony JC. Adolescent cannabis problems and young adult depression: male-female stratified propensity score analyses. Am J Epidemiol. 2008;168:592–601. doi:https://doi.org/10.1093/aje/kwn184.
- Feingold D, Rehm J, Lev-Ran S. Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study. Psychiatry Res. 2017;251:225–34. doi:https://doi.org/10.1016/j.psychres.2017.02.027.
- Pacek LR, Martins SS, Crum RM. The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample. J Affect Disord. 2013;148:188–95. doi:https://doi.org/10.1016/j.jad.2012.11.059.
- Hunt GE, Malhi GS, Cleary M, Lai HM, Sitharthan T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: systematic review and meta-analysis. J Affect Disord. 2016;206:331–349.
- Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord. 2001;3:181–88. doi:https://doi.org/10.1034/j.1399-5618.2001.30403.x.
- Kawa I, Carter JD, Joyce PR, Doughty CJ, Frampton CM, Wells JE, et al. Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord. 2005;7:119–125.
- Morgan VA, Mitchell PB, Jablensky AV. The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian national study of low prevalence (Psychotic) Disorders. Bipolar Disord. 2005;7:326–37. doi:https://doi.org/10.1111/j.1399-5618.2005.00229.x.
- Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE Jr, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64:57–64.
- van Rossum I, Boomsma M, Tenback D, Reed C. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis. 2009;197:35–40.
- Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, Nolen WA, Grunze H, Leverich GS, Keck PE, et al. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167:708–15.
- Braga RJ, Burdick KE, Derosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res. 2012;200:242–245.
- Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res. 2013;209:459–465.
- Weinstock LM, Gaudiano BA, Wenze SJ, Epstein-Lubow G, Miller IW. Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder. Compr Psychiatry. 2016;65:57–62.
- Cotton SM, Lambert M, Berk M, Schimmelmann BG, Butselaar FJ, McGorry PD, Conus P. Gender differences in first episode psychotic mania. BMC Psychiatry. 2013;13:82.
- Shand FL, Degenhardt L, Slade T, Nelson EC. Sex differences amongst dependent heroin users: histories, clinical characteristics and predictors of other substance dependence. Addict Behav. 2011;36:27–36.
- Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20:10–14. doi:https://doi.org/10.1111/j.1365-2826.2008.01671.x.
- D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572.
- Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92:476–81. doi:https://doi.org/10.1016/j.lfs.2012.06.009.
- Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19:293–300.
- Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 2008;8:1037–48. doi:https://doi.org/10.1586/14737175.8.7.1037.
- Lenroot RK, Gogtay N, Greenstein DK, Wells EM, Wallace GL, Clasen LS, Blumenthal JD, Lerch J, Zijdenbos AP, Evans AC, et al. Sexual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage. 2007;36:1065–73.
- Realini N, Rubino T, Parolaro D. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res. 2009;60:132–38. doi:https://doi.org/10.1016/j.phrs.2009.03.006.
- Richmond-Rakerd LS, Slutske WS, Wood PK. Age of initiation and substance use progression: a multivariate latent growth analysis. Psychol Addict Behav. 2017;31:664–75. doi:https://doi.org/10.1037/adb0000304.
- Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol. 2010;160:511–22. doi:https://doi.org/10.1111/j.1476-5381.2010.00721.x.
- Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, Abdellaoui A, Nivard MG, Baselmans BML, Ong J-S, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 2018;21:1161–70.
- Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57:1117–27.
- Hoenicka J, Garrido E, Ponce G, Rodríguez-Jiménez R, Martínez I, Rubio G, et al. Sexually dimorphic interaction between the DRD1 and COMT genes in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:948–954.
- Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212–1213.
- Moore TH, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328.
- Tu AW, Ratner PA, Johnson JL. Gender differences in the correlates of adolescents’ cannabis use. Subst Use Misuse. 2008;43:1438–63. doi:https://doi.org/10.1080/10826080802238140.
- Matheson J, Sproule B, Di Ciano P, Fares A, Le Foll B, Mann RE, Brands B. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. Psychopharmacology (Berl). 2020;237:305–316.
- Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010;92:370–85.
- Agrawal A, Lynskey MT. Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the national epidemiological survey on alcohol and related conditions. Drug Alcohol Depend. 2007;88:300–07. doi:https://doi.org/10.1016/j.drugalcdep.2006.10.003.
- Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, et al. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biol Psychiatry. 2016;79:997–1005.
- Hirvonen J, Goodwin RS, Li C-T, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17:642–49.
- D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008;33:2505–2516.
- Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S. Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev. 2016;64:359–381.
- Lopez HH. Cannabinoid-hormone interactions in the regulation of motivational processes. Horm Behav. 2010;58:100–10. doi:https://doi.org/10.1016/j.yhbeh.2009.10.005.
- Riebe CJ, Hill MN, Lee TT, Hillard CJ, Gorzalka BB. Estrogenic regulation of limbic cannabinoid receptor binding. Psychoneuroendocrinology. 2010;35:1265–1269.
- Costafreda SG, Brammer MJ, David AS, Fu CH. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res Rev. 2008;58:57–70.
- Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18:1034–40.
- Krebs-Kraft DL, Hill MN, Hillard CJ, McCarthy MM. Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior. Proc Natl Acad Sci U S A. 2010;107:20535–40.
- Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34:637–644.
- Morgan CJ, Page E, Schaefer C, Chatten K, Manocha A, Gulati S, et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry. 2013;202:381–382.
- Boileau I, Mansouri E, Williams B, Le Foll B, Rusjan P, Mizrahi R, Tyndale RF, Huestis MA, Payer DE, Wilson AA, et al. Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [11C]CURB. Biol Psychiatry. 2016;80:691–701. doi:https://doi.org/10.1016/j.biopsych.2016.04.012.
- Simon NM, Zalta AK, Worthingston JJ 3rd, Hoge EA, Christian KM, Stevens JC, Pollack MH. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006;23:373–376.
- Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003;60:837–844.
- Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325:1195–1198.
- Rubino T, Sala M, Viganò D, Braida D. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology. 2007;32:2036–2045.
- Pedersen W, Mastekaasa A, Wichstrom L. Conduct problems and early cannabis initiation: a longitudinal study of gender differences. Addiction. 2001;96:415–31. doi:https://doi.org/10.1046/j.1360-0443.2001.9634156.x.
- Alegria AA, Petry NM, Liu SM, Blanco C, Skodol AE, Grant B, Hasin D. Sex differences in antisocial personality disorder: results from the national epidemiological survey on alcohol and related conditions. Personal Disord. 2013;4:214–222.
- Coffey C, Lynskey M, Wolfe R, Patton GC. Initiation and progression of cannabis use in a population-based Australian adolescent longitudinal study. Addiction. 2000;95:1679–1690.
- Fonseca F, Robles-Martínez M, Tirado-Muñoz J, Alías-Ferri M, Mestre-Pintó JI, et al. A gender perspective of addictive disorders. Curr Addict. 2021;89–99:1–11.
- Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D’Souza DC, Howes OD, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7:344–53.
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593–602.